NCT07640139
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Enrolling by Invitation
Not specifiedAges 18–64ObservationalIndiana UniversityInvestigator-initiated
~125,000 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Incretin-based therapies (GLP-1 and GLP-1/GIP)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in subject body weight.
Measured over 6 months periods from 2018 to 2029
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesIndiana1
Study leadership
- Joshua R Vest, PhD, MPH · PRINCIPAL_INVESTIGATOR · Indiana University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Change in subject body weight.6 months periods from 2018 to 2029
Measured in pounds.
- Change in subject body mass index (BMI).6 months periods from 2018 to 2029
Defined as Weight (kg) / height (m)2.
- Change in obesity and overweight classification.6 months periods from 2018 to 2029
Body mass index categorized according to Centers for Disease Control \& Prevention groupings (i.e., normal, overweight, class 1 obesity, class 2 obesity, class 3 obesity)